Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
03 Outubro 2024 - 10:00AM
Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company
focused on developing highly selective 5-HT2 agonists for the
treatment of drug-resistant epilepsy, depression, and other CNS
disorders, is excited to announce its participation in the upcoming
scientific conferences:
- Neuroscience 2024 annual meeting, organized by
the Society for Neuroscience (SfN), will take place in Chicago,
October 5–9.
- Therapeutic Development at NINDS Chicago,
October 7, 2024. Bright Minds will discuss its progress in epilepsy
(ETSP) and pain (PSPP) programs and collaboration with NIH.
- BIO-Europe, Europe's leading partnering event
– Stockholm, Sweden, November 4-6.
- Chicago Biocapital Summit, a showcase of
Midwest biotech innovation, organized by Chicago Biomedical
Consortium – Chicago, November 6-7.
- AES Annual Meeting 2024, Los Angeles, December
6-10. Bright Minds Biosciences will present data for BMB-101, lead
5-HT2C agonist for the treatment of rare epilepsies.
Presentations by Bright Minds Biosciences will include:
Title: Novel 5-HT2A-selective agonists with
well-characterized PK profile and short duration of
actionPoster Number: PSTR041.28 /
N5Presentation date and location: October 5, 2024,
1:00 PM - 5:00 PM MCP Hall A
Title: Phase I Study to Evaluate the Safety,
Tolerability, and Pharmacokinetics of Single and Multiple Ascending
Oral Doses of novel 5-HT2C agonist, BMB-101, in Fed and Fasted
Adult Healthy Human VolunteersPoster Number:
1.532Presentation date and location: Poster
Session 1, Saturday, December 7. South Hall H,
Level 1
Title: BMB-101 and Biased 5-HT2C Agonism: A
Novel Approach for Sustained Epilepsy ManagementPoster
Number: 1.533Presentation date and
location: Poster Session 1, Saturday, December 7.
South Hall H, Level 1
Option Grants
The Company is also pleased to announce that it has granted
70,000 options (the “Options”) to employees and members of the
board of directors, to purchase 70,000 Shares pursuant to the
Company’s share option plan. The Options are exercisable at an
exercise price of $1.65 per Share for a period of five (5) years
from the date of grant. The Options are subject to vesting periods
over the course of the term of the Options.
About BMB-101
BMB-101 is a novel scaffold 5-HT2C Gq-protein biased agonist
developed using structure-based drug design. It was explicitly
designed for chronic treatment of neurological disorders where
tolerance and drug resistance are common issues. Biased agonism at
the 5-HT2C receptor is one of its key features and adds another
layer of functional selectivity within a well-validated target.
BMB-101 works exclusively via the Gq-protein signaling pathway and
avoids beta-arrestin activation, which is crucial to minimize the
risk of receptor desensitization and tolerance development. This
provides a novel mechanism, anti-epileptic drug designed to provide
sustained seizure relief in hard-to-treat patient populations. In
preclinical studies, BMB-101 has demonstrated efficacy in animal
models of Dravet Syndrome and numerous models of generalized
seizures.
In Phase 1 clinical studies, BMB-101 was given to 64 healthy
volunteers in a Single Ascending Dose (SAD), Multiple Ascending
Dose (MAD) and food-effects study. BMB-101 was demonstrated to be
safe and well tolerated at all doses. No Serious Adverse Events
(SAEs) were observed, and Adverse Events (AEs) were mild in nature
and in line with on-target effects for serotonergic drugs.
An extensive target-engagement study was conducted using both
fluid biomarkers (transient prolactin release) and physical
biomarkers (Quantitative Electroencephalogram, qEEG). Both methods
confirmed robust central target engagement. A qEEG signature
typical for anti-epileptic drugs was observed, with a selective
depression of EEG power at frequencies observed during epileptic
seizures. Furthermore, a potentiation of frontal gamma-power was
observed in this study which could indicate the potential for
improved cognition.
About Bright Minds BiosciencesBright Minds
Biosciences is a biotechnology company developing innovative
treatments for patients with neurological and psychiatric
disorders. Our pipeline includes novel compounds targeting key
receptors in the brain to address conditions with high unmet
medical need, including epilepsy, depression, and other CNS
disorders. Bright Minds is focused on delivering breakthrough
therapies that can transform patients' lives.
Bright Minds Biosciences has developed a unique platform of
highly selective serotonergic agonists exhibiting selectivity at
different serotonergic receptors. This has provided a rich
portfolio of NCE programs within neurology and psychiatry.
Forward-Looking Statements
This news release contains “forward-looking
information”. Often, but not always, forward-looking statements can
be identified by the use of words such as “plans”, “expects”, “is
expected”, “budget”, “scheduled”, “estimates”, “forecasts”,
“intends”, “anticipates”, or “believes” or variations (including
negative variations) of such words and phrases, or state that
certain actions, events or results “may”, “could”, “would”, “might”
or “will” be taken, occur or be achieved. Forward-looking
statements in this news release include design, progress, and
completion of the BREAKTHROUGH Study, future clinical development
of BMB-101, and future intended use or therapeutic benefit of
BMB-101 to treat refractory epilepsy disorders. A variety of
factors, including known and unknown risks, many of which are
beyond our control, could cause actual results to differ materially
from the forward-looking information in this news release. These
factors include the company’s financial position and operational
runway, regulatory risk to operating in the pharmaceutical
industry, and inaccuracies related to the assumption made by
management relating to general availability of resources required
to operate the studies noted in this news release. Additional risk
factors can also be found in the Company’s public filings under the
Company’s SEDAR+ profile at www.sedarplus.ca. Forward-looking
statements contained herein are made as of the date of this news
release and the Company disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or results or otherwise. There can be no assurance
that forward-looking statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. The Company undertakes no
obligation to update forward-looking statements if circumstances,
management’s estimates or opinions should change, except as
required by securities legislation. Accordingly, the reader is
cautioned not to place undue reliance on forward-looking
statements.
The Canadian Securities Exchange has neither
approved nor disapproved the information contained herein and does
not accept responsibility for the adequacy or accuracy of this news
release.
Contact Information
Alex VasilkevichChief Operating OfficerBright Minds Biosciences
Inc. Phone: (414)7316422Email: alex@brightmindsbio.com Website:
www.brightmindsbio.com
Bright Minds Biosciences (NASDAQ:DRUG)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Bright Minds Biosciences (NASDAQ:DRUG)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024